Evidence map›Paper›PMID 40235102›Full record

ArticleKorean journal of ophthalmology : KJO2025

Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection.

Myung Ae Kim, Soon Il Choi, Jong Min Kim, Hyun Sub Oh, Yong Sung You, Won Ki Lee, Soon Hyun Kim, Oh Woong Kwon, Ju Young Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Korean journal of ophthalmology : KJO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Myung Ae KimRetina Center, Nune Eye Hospital, Seoul, Korea.
Soon Il ChoiRetina Center, Nune Eye Hospital, Seoul, Korea.
Jong Min KimRetina Center, Nune Eye Hospital, Seoul, Korea.
Hyun Sub OhRetina Center, Nune Eye Hospital, Seoul, Korea.
Yong Sung YouRetina Center, Nune Eye Hospital, Seoul, Korea.
Won Ki LeeRetina Center, Nune Eye Hospital, Seoul, Korea.
Soon Hyun KimRetina Center, Nune Eye Hospital, Seoul, Korea.
Oh Woong KwonRetina Center, Nune Eye Hospital, Seoul, Korea.
Ju Young KimRetina Center, Nune Eye Hospital, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the outcomes of brolucizumab reinjection after intraocular inflammation (IOI) development.

methodsThis retrospective study analyzed patients with brolucizumab injections from April 2021 to January 2024. Patients who developed IOI after brolucizumab were included and categorized into subgroups depending on reinjection, discontinuation, and further IOI development.

resultsA total of 472 eyes of 432 patients received brolucizumab injections. Thirty-eight cases developed IOI at least once, and 25 continued brolucizumab. Sixteen cases had no more IOI events, and nine experienced a second or more IOI events. Among the nine cases, three maintained brolucizumab injections despite IOI recurrence. The incidence of IOI was 8.1% based on the number of eyes (38 of 472 eyes) and 2.0% based on the number of brolucizumab injections (50 of 2,468 injections). The incidence of occlusive retinal vasculitis was 0.2% (1 of 472 eyes). The recurrence rate was 23.7% (9 of 38 eyes). The average number of injections between the first brolucizumab injection and the injection date on which IOI first developed was 2.15 times in the no-reinjection group, 3.44 times in the no-IOI-recurrence group, and 2.0 times in the second-IOI-episode group. Time to IOI occurrence in cases with first IOI episode was 18.60 ± 16.73 days, with 15 cases developing IOI within 1 week.

conclusionsThis study elucidates the real-world incidence of brolucizumab associated IOIs, with a description of information related to reinjections after the IOI episodes. A comprehensive understanding of brolucizumab reinjection is essential for its optimal utilization.

Indexed as

Antibodies, Monoclonal, HumanizedEndophthalmitisVisual AcuityAgedAngiogenesis InhibitorsFemaleFollow-Up StudiesFundus OculiHumansIncidenceIntravitreal InjectionsMaleMiddle AgedRecurrenceRetrospective StudiesTomography, Optical CoherenceAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedbrolucizumabBrolucizumabIntravitreal injectionsMacular degenerationUveitis

Identifiers

PMID40235102
PMCPMC12178686

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.